CD4 and myeloid sarcoma: A clinical study enrolling 12 MS relapsing–remitting patients in stable condition and 14 healthy controls revealed that members of the miR-106b-25 cluster were down-regulated in CD4+CD25highCD127dim/−T regulatory cells of MS patients [56] (Table 2).